Abstract:During a 3 year period, seventy patients aged 53 +/- 16 years with a total of 73 arrhythmias were treated over a mean period of 6.8 months (maximum 27 months) with oral propafenone, the usual dose being 900 mg/day. The study covered the whole spectrum of cardiac arrhythmias (32 supraventricular, 41 ventricular), and their relation to the autonomic nervous system. The efficacy was scored from 1 (no effect) to 5 (complete control) as judged by the clinical response, the results of Holter monitoring (175 control and 133 test recordings on therapy), and a comparison was made between the effects of propafenone and other antiarrhythmics: quinidine-like drugs, beta-blockers and amiodarone. With respect to supraventricular arrhythmias: 9 cases of vagally-induced atrial flutter and fibrillation were unaffected by propafenone (mean score = 1.1). On the other hand, the drug was very effective (mean score = 4.1) in 8 cases of adrenergic atrial arrhythmias. In 12 arrhythmias with more varied mechanisms (extrasystoles, tachysystole, paroxysmal atrial fibrillation) an intermediate score was obtained (2.8). Three cases of resistant junctional tachycardia due to reentry were improved. At ventricular level, 5 cases of extrasystole sensitive to quinidine were also improved by propafenone (4.6); the difference was more clearcut in 8 cases of benign idiopathic tachycardia (propafenone: 4.1, and quinidine: 2.4). This was more marked in 13 cases of more severe arrhythmia in diseased hearts in which the effect of propafenone (4.1) was superior even to that of amiodarone. However, propafenone was less effective (3.3) than amiodarone in 4 cases of severe polymorphic idiopathic ventricular tachycardia closely related to the autonomic nervous system. The antiarrhythmic effect of propafenone was appreciable in 10 cases of resistant post-infarction ventricular tachycardia, eventually in association with amiodarone. Slowing of the sinus rhythm (-11.6%) with no change in the day/night ratio was due to beta-inhibition. However, in toxic doses this may progress to sinoatrial block (9 cases). A lengthening of the PR interval and duration of QRS was common, but this was not complicated by torsade de pointes, one case of which was successfully treated by propafenone. Secondary gastro-intestinal effects and vertigo were rarely severe enough to warrant stopping therapy. In conclusion, these results show that the introduction of propafenone is a valuable therapeutic advance in the treatment of arrhythmias, especially in those with a favoring adrenergic mechanism.

Propafenone-associated Gross Hematuria: A Case Report and Review of the Literature

A case of propafenone toxicity in the setting of dehydration and acute kidney injury

Propafenone-induced liver injury in an elderly patient with paroxysmal atrial fibrillation--a new case report and literature review

One Case of Piribedil-Induced Syncope

Effect of Oral Propafenone on Reversing Paroxysmal Atrial Fibrillation with No Rheumatic Disease

[Anti-arrhythmic effect of oral propafenone. Apropos of 70 cases]

Benzbromarone as a possible cause of acute kidney injury in patients with urolithiasis: Two case reports.

Effect of Cyp2d6*10 Genotype on Propafenone Pharmacodynamics in Chinese Patients with Ventricular Arrhythmia

Case Report: Pink Urine Syndrome Following Exposure to Propofol: A Rare, Impressive but Benign Complication

Metabolic Activation and Cytotoxicity of Propafenone Mediated by CYP2D6.

Appraisal of efficacy and safety of imported propafenone in treatment of ventricular premature beats

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases

Risk factors associated with the severity of adverse drug reactions by Xiyanping injection: A propensity score-matched analysis

Propacetamol poses a potential harm of adverse hypotension in male and older patients

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system

Role of the interaction between puerarin and the erythrocyte membrane in puerarin-induced hemolysis

Clopidogrel-induced neutropenia in an 80-year-old patient with chronic kidney disease who underwent percutaneous coronary intervention: a case report and literature review

Clinical features of adverse events associated with Xiyanping-Ribavirin combination: A systematic review

PARP inhibitor-related haemorrhages: What does the real-world study say?

European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias

Posaconazole-associated severe hyperbilirubinemia in acute myeloid leukemia following chemotherapy: A case report.